With no explanation, chose the best option from "A", "B", "C" or "D". (2013) (ex plaining the FDA’s view that “promoting a drug for an off-label use is a violation” of the FDCA’s misbranding provisions). Based on this view, the FDA has recovered millions of dollars in settlements from drug manufacturers that have engaged in off-label promotion. See, e.g., id. at 232 (citing Press Release, U.S. Dep’t of Justice, Justice Department Announces Largest Health Care Fraud Settlement in Its History, (Sept. 2, 2009) (trumpeting a mul-ti-billion dollar fine imposed against a drug company that promoted its drugs for uses and dosages that the FDA specifically declined to approve)). The FDA’s informal interpretation of a statute it administers is entitled to some deference from courts. See Skidmore v. Swift & Co., 323 U.S. 134, 140, 65 S.Ct. 161, 89 L.Ed. 124 (1944) (<HOLDING>). But courts have not always agreed with the

A: holding that where statute is ambiguous deference is appropriately accorded to agencys interpretation
B: holding that an agencys interpretation of its own regulations is entitled to deference
C: holding that an agencys informal interpretation of a statute it administers is entitled to deference to the extent it has the power to persuade
D: holding that deference is owed to state agencys interpretation of state law
C.